Evaluating the efficacy of ziprasidone in improving cognition,quality of life and clinical symptom in schizophrenia

doi:10.3969/j.issn.1006-7795.2018.02.009

Abstract

Abstract: Objective To investigate the efficacy of ziprasidone in improving cognitive function, quality of life and clinical symptom in schizophrenia. Methods Fifty-four patients were randomized to either ziprasidone or haloperidol treatment group. The clinical characters, cognition abilities and quality of their life were re-examined at follow-up intervals up to 16 weeks. Results Ziprasidone significantly improved the scores of Wisconsin card sorting test (WCST) error number at 12th week and 16th week, WCST persistent error number at 16th week, compared with baseline(P<0.05), but not in haloperidol group. Ziprasidone significantly improved the reaction time of continuous performance test(CPT) and the scores of digit span test at 12th and 16th week, compared with baseline(P<0.05), but not in haloperidol group. Both ziprasidone and haloperidol groups showed significant improvement in PANSS scores(F=77.10,P=0.000), with no significant difference between them. Ziprasidone significantly improved the scores of Quality of Life Enjoyment and Satisfaction Questionnaire(F=18.39,P=0.000) compared with baseline, but not in haloperidol group. Conclusion Ziprasidone can improve the attention, working memory,executive function and quality of life in schizophrenia patients. Same effect hasn't been observed in the group treated with haloperidol. Both ziprasidone and haloperidol showed similar clinical effects on psychiatric symptom in schizophrenia.

Key words: schizophrenia, cognitive function, quality of life, ziprasidone

CLC Number:

R749

Zhu Hong, Zhi Lihua, Jia Hongxiao. Evaluating the efficacy of ziprasidone in improving cognition,quality of life and clinical symptom in schizophrenia[J]. Journal of Capital Medical University, 2018, 39(2): 199-203.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2018.02.009

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2018/V39/I2/199

References

[1] Zaragoza D S, Bobes J, García-Portilla M P, Morralla C. Cognitive performance associated to functional outcomes in stable outpatients with schizophrenia[J]. Schizophr Res Cogn, 2015, 2(3):146-158.
[2] Mattei C, Rapagnani M P, Stahl S M. Ziprasidone hydrocloride:what role in the management of schizophrenia[J]. J Cent Nerv Syst Dis, 2011, 3:1-16.
[3] 孙志刚, 宋丽华, 李素水, 等. 改善精神分裂症认知障碍与5-羟色胺1A受体的关系研究进展[J]. 临床精神医学杂志, 2016, 26(5):350-352.
[4] Hamilton S H, Revicki D A, Genduso L A, et al. Olanzapine versus placebo and haloperidol:quality of life and efficacy results of the north American double-blind trial[J]. Neuropsychopharmacology, 1998, 18(1):41-49.
[5] GAM B, Mesholam-Gately R I, Toulopoulou T, et al. Heritability of neuropsychological measures in schizophrenia and nonpsychiatric populations:a systematic review and Meta-analysis[J]. Schizophr Bull, 2017,43(4):788-800.
[6] Gardner D M, Murphy A L, O'Donnell H, et al. International consensus study of antipsychotic dosing[J]. Am J Psychiatry,2010, 167(6):686-693.
[7] 李新峰. 齐拉西酮对首发精神分裂症患者疗效及认知功能的影响[J]. 中国健康心理学杂志,2015, 23(8):1140-1142.
[8] Désaméricq G, Schurhoff F, Meary A, et al. Long-term neurocognitive effects of antipsychotics in schizophrenia:a network meta-analysis[J]. Eur J Clin Pharmacol,2014, 70(2):127-134.
[9] Chen X, Zhang Z H, Song Y, et al. A paired case-control comparison of ziprasidone on visual sustained attention and visual selective attention in patients with paranoid schizophrenia[J]. Eur Rev Med Pharmacol Sci,2015,19(16):2952-2956.
[10] Malhotra A K, Burdick K E, Razi K, et al. Ziprasidone-induced cognitive enhancement in schizophrenia:specificity or pseudospecificity[J]. Schizophr Res, 2006, 87(1-3):181-184.
[11] Garver D L, Holcomb J A, Christensen J D. Cerebral cortical gray expansion associated with two second-generation antipsychotics[J]. Biol Psychiatry, 2005, 58(1):62-86.
[12] Stip E, Cherbal A, Luck D, et al. A neuroimaging study of emotion-cognition interaction in schizophrenia:the effect of ziprasidone treatment[J]. Psychopharmacology (Berl), 2017, 234(7):1045-1058.
[13] 陈颖, 刘善明, 邓红,等. 精神分裂症患者社会功能的影响因素[J]. 中华精神科杂志,2011, 44(2):126.

[1]	Li Qiong, Zhao Jianhua, Liu Hao, Wang Fan, Li Qing, Chen Xiyan, Cai Ruiyan, Wu Qingwu, Zhang Jian, Ji Sibei, Lu Chengbiao, Li Shaomin. The relationship between serum CX3CL1 level and cognitive dysfunction in patients with white matter hyperintensity [J]. Journal of Capital Medical University, 2023, 44(1): 6-12.
[2]	Lian Siyuan, Wu Han, Han Jinxiang, Xiao Cunli, Ren Yanping, Jin Wenqing, Wang Wen, Ma Xin. Study of related factors on self-report effects of rehabilitation in schizophrenia patients [J]. Journal of Capital Medical University, 2022, 43(2): 233-238.
[3]	Ren Yanping, Zhang Junyan, Wu Han, Luo Jiong, Yang Chunlin, Ma Xin, Jiang Wei. Comparison on the early efficacy and cognitive effect of magnetic seizure therapy and modified electroconvulsive therapy for depressive episodes [J]. Journal of Capital Medical University, 2022, 43(2): 239-243.
[4]	Li li, Liu Chaomeng, Ren Yanping, Yang Chunlin, Ma Xin. Research advances of modified electroconvulsive therapy for first-episode schizophrenia [J]. Journal of Capital Medical University, 2022, 43(2): 249-253.
[5]	Guo Chengwei, Zhou Jiaojiao, Feng Yuan, Yang Yunping. A comparative study of self esteem between schizophrenics and normal people [J]. Journal of Capital Medical University, 2022, 43(2): 294-298.
[6]	Yang Liuqing, Tian Hongmei, Shi Hanping. Research and progress on three types of dietary patterns and chronic diseases [J]. Journal of Capital Medical University, 2022, 43(2): 311-320.
[7]	Chen Xi, Ma Denglei, Li Lin. Effects of icariin on the behavioral changes, demyelination and neuroinflammation in mice with cuprizone-induced schizophrenia [J]. Journal of Capital Medical University, 2021, 42(5): 761-767.
[8]	Liu Yijun, Lin Xiangying, Zhang Yan. Validity and reliability of the Chinese version ofWorld Health Organization Quality of Life-BREF among patients with end-stage renal disease [J]. Journal of Capital Medical University, 2021, 42(4): 635-641.
[9]	Li Zhi, Zhang Jun, Dai Yuexuan, Qin Mingyang, Liang Furu. Effect and mechanism of blood glucose fluctuation on cognitive function in type 2 diabetic rats [J]. Journal of Capital Medical University, 2021, 42(3): 347-353.
[10]	Qin Qi, Tang Yi, Qu Yida, Zhou Aihong, Ding Jianping, Yin Yunsi, Liu Yong, Jia Jianping. Study on the association between white matter connectivity changes and cognitive deficits in vascular cognitive impairment no dementia using diffusion tensor imaging [J]. Journal of Capital Medical University, 2021, 42(3): 373-384.
[11]	Ning Yanzhe, Zhu Hong, Song Nan, Zheng Sisi, Li Ziyan, Li Jiajia, Ma Rui, Jia Hongxiao. A preliminary study on efficacy for Shi-zhen-an-shen granules on cognitive impairments in prodromal schizophrenia [J]. Journal of Capital Medical University, 2021, 42(3): 404-407.
[12]	Yi Yuwei, Yan Fang, Jin Yuhong, Xiao Cunli. Analysis of influencing factors of risk behaviors of inpatients with schizophrenia [J]. Journal of Capital Medical University, 2021, 42(2): 323-327.
[13]	Sha Sha, Zhao Xixi, Han Chuanliang, Peng Xing, Zhang Pei, Dong Wen, Yin Jingjing, Wang Changming. Correlation between alpha activity and cognitive in resting electroencephalogram of schizophrenia [J]. Journal of Capital Medical University, 2021, 42(1): 117-124.
[14]	Zhang Ying, Wang Ruomei, Li Gang. Cognitive function, emotion management and its influencing factors in stable schizophrenia [J]. Journal of Capital Medical University, 2021, 42(1): 143-147.
[15]	Liu Xinyao, Ma Chao, Jia Hongxiao. Current status of research concerning animal models of cognitive impairment of schizophrenia [J]. Journal of Capital Medical University, 2020, 41(1): 50-54.